Tracy Staton

Biography for Tracy Staton

Tracy Staton, Senior Editor

Tracy Staton is the editor of FiercePharma and FiercePharmaMarketing. She has been a freelance writer for eight years, but before that served as editor of the Dallas Business Journal, editor of Texas Business magazine, and a senior editor at American Way, the inflight magazine of American Airlines. She is based in Vermont, and can be reached at or find her on LinkedIn.

Articles by Tracy Staton

UPDATED: Blockbuster-to-be cancer meds outclass other big launches--except Sovaldi and statins

No question, immuno-oncology drugs are the hottest tickets in cancer--and among the hottest across the board. But PD-1/PD-L1 treatments, including Merck & Co.'s Keytruda and Bristol-Myers Squibb's Opdivo, aren't the first to bear big sales expectations. How do immuno-oncology forecasts stack up against other notable drug launches?

Leaked TPP document shows pharma still angling for pricing influence

The Obama administration is backing off of drug-price protections in the big Trans-Pacific Partnership treaty now under negotiation, The New York Times reports. But U.S. negotiators are still pressing for more power to get involved in government decisions on reimbursement rates.

You're free to speak, FDA tells Amarin in bid to deflate free-speech suit

Pharma marketers are closely watching Amarin's lawsuit demanding the right to talk up the off-label uses for its cardiovascular drug Vascepa. After all, if the legal attack against FDA regulations succeeds, that gives credence to drugmakers' free speech argument--and could open up new worlds of drug promotion.

Mylan expands cancer drug recall on particle contamination worries

Sterile injectable drugs are notoriously tricky to manufacture. Mylan has found that out the hard way, and it's now expanding a recall of cancer drugs that it began in April because they may contain particulate.

No red flags in Januvia heart study means a big win for Merck

Last month, Merck & Co. said Januvia passed its heart safety test. Now, the much-anticipated TECOS trial has had its airing at the American Diabetes Association meeting, and the study authors say the drug is in the clear.

Pfizer scientist warned execs about Zoloft and birth defects, lawyers say

Pfizer executives were warned by one of their own scientists about a potential link between the antidepressant med Zoloft and birth defects, accordingly to a newly surfaced document cited by Bloomberg.

U.S. poised to spend $50B on just 10 'breakthrough' meds in 10 years

U.S. payers are striking out at drug spending again, highlighting the cost to taxpayers. According to a commissioned report, 10 hot new "breakthrough" meds are expected to cost publicly funded healthcare plans more than $50 billion over the next decade.

How to avoid the 'magic pill' issue with weight loss meds? Honesty, journal says

Weight Watchers figured it out and so did "The Biggest Loser." Dieting and exercise to lose weight is more effective when done with support.

Top Novartis brass backs results-based drug pricing

Novartis CEO Joe Jimenez and Chairman Joerg Reinhardt sang the same tune on drug prices in separate interviews over the weekend, backing performance-based drug deals while pointing the finger at other healthcare expenses for driving up overall spending.

Sanofi bags 'breakthrough' tag for new Genzyme rare disease med

Sanofi's rare disease-focused unit Genzyme picked up the FDA's coveted breakthrough-therapy designation for a drug designed to treat a form of Niemann-Pick disease.